Abstract:Objective To investigate the clinical efficacy of albumin-paclitaxel combined with platinum-based chemotherapy and intensity-modulated radiotherapy in the treatment of advanced esophageal cancer. Methods Sixty-two patients with advanced esophageal cancer treated in the First Affiliated Hospital of Hebei North University from March 2020 to March 2022 were selected as the subjects prospectively. According to the simple random number table method, patients were divided into study group (31 cases) and control group (31 cases). The control group received intensity-modulated radiotherapy combined with platinum-based chemotherapy, and the study group received albumin paclitaxel on the basis of the control group. 3 weeks as a cycle, a total of 4 cycles of treatment. The tumor control rates, the serum vascular endothelial growth factor（VEGF）, B-cell lymphoma 2（Bcl-2）, P53 antibody, secreted protein Dikkopf-1（DKK1）, cytoplasmic thymidine kinase 1（TK1）, the 1-year survival rate and the degree of myelosuppression during the treatment period were compared between two groups. Results The tumor control rate of the study group was significantly higher than that of the control group（90.32% vs 67.74%, P＜0.05）. After the course of treatment, the serum expression levels of VEGF, Bcl-2, P53 antibody, DKK1 and TK1 of the study group were significantly lower than those of the control group（P＜0.05）. The 1-year survival rate of the study group was significantly higher than that of the control group（77.42% vs 51.61%, P＜0.05）. The bone marrow suppression score of the study group was significantly lower than that of the control group（P＜0.01）.Conclusions Albumin-paclitaxel combined with platinum-based chemotherapy and intensity-modulated radiotherapy for advanced esophageal cancer has good curative effect, can effectively improve the 1-year survival rate of patients, reduce the expression levels of serum VEGF, Bcl-2, P53 antibodies, DKK1 and TK1, and inhibit tumor growth and proliferation, and less toxic side effects.